Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen®

Core Viewpoint - Niagen Bioscience, Inc. has expanded its NAD+ precursor intellectual property portfolio with the granting of U.S. Patent No. 12,558,367, which pertains to the use of nicotinamide riboside (NR) and its derivatives in intravenous and injectable formulations [1] Company Developments - The newly granted patent enhances the company's position as a leader in the NAD+ market, focusing on healthy aging [1] - CEO Rob Fried emphasized the significance of this patent in advancing the company's research and product development efforts [1]